Viatris | VTRS - Ebitda

Stock Price
16.48
Daily Change
-0.78 -4.52%
Monthly
17.63%
Yearly
86.43%
Q2 Forecast
16.15

Viatris reported $1.05B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Celltrion KRW 17.79B 356.77B Dec/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Organigram Holdings CAD 5.26M 884K Dec/2025
Pharma Mar EUR 2.71M 42.25M Mar/2026
Qiagen NV USD 249.69M 56.53M Dec/2025
Sartorius EUR 267.3M 10.1M Mar/2026
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1.05B 46.4M Mar/2026
Zealand Pharma A/S -727.47M 285.54M Dec/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 882.7M 351.1M Mar/2026